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Fasting insulin, adiponectin, high-sensitivity C-reactive protein (hs-CRP), and interleukin-1 receptor antagonist (IL-1Ra) were
determined in 278 men and 273 women with blood pressure ≥130 and/or ≥85 mmHg and/or with antihypertensive medication.
Metabolic syndrome (MetS) with the National Cholesterol Education Program (NCEP) criteria was observed in 35% of men and
34% of women. Men with MetS had lower hs-CRP and IL-1Ra than women. The absolute gender diﬀerence in adiponectin was
smallerandthoseinIL-1Raandhs-CRPweregreaterinsubjectswithMetScomparedtothosewithout.Afteradjustmentwithbody
mass index the association between insulin and the odd’s ratio (OR) for MetS remained signiﬁcant in both genders, in females also
the association between the OR for MetS and adiponectin. There are gender diﬀerences in subjects with elevated blood pressure
and MetS with respect to inﬂammatory markers and the relationship between adiponectin levels and MetS.
Copyright © 2009 Tiina Ahonen et al. This is an open access article distributed under the Creative Commons Attribution License,
which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
1.Introduction
Elevated blood pressure (BP) is associated with insulin
resistance or hyperinsulinemia [1–4] and hypertension has
been included in the deﬁnition of metabolic syndrome
(MetS) [5]. MetS, that is, a cluster of cardiovascular risk
factors accompanied by an increased risk of cardiovascular
disease (CVD) and type 2 diabetes, is common in obese
subjects with a sedentary lifestyle [6–9]. Similarly, smokers
and heavy alcohol users often have MetS [10, 11].
Adiposetissuesecretesavarietyofinﬂammatorymarkers
associated with elevated BP, insulin resistance, and MetS
[12]. Adiponectin concentrations are low in subjects with
essential hypertension [13], and hypoadiponectinemia has
been considered to be a potential additional component
of MetS [14, 15]. High levels of high-sensitivity C-reactive
protein (hs-CRP) are often observed in hypertensive subjects
[16] and in subjects with MetS [17]. Elevated levels of
interleukin-1β (IL-1β) and interleukin-1 receptor antagonist
(IL-1Ra) have been detected in subjects with essential
hypertension [18–21] and they are known to contribute to
the development of insulin resistance and MetS [18, 22]. The
IL-1Ra level has been shown to be the most sensitive marker
for cytokine response in the prediabetic state [23].
MetShasbeenshowntopredictCVDeventsinhyperten-
sive subjects independently of traditional risk factors [24].
MetS in hypertensive subjects impairs total arterial compli-
ance, and MetS in subjects with untreated hypertension has
been shown to be associated with aortic stiﬀness [25, 26].
Earlierithasbeenshownthattherearegenderdiﬀerences
in the levels of hs-CRP and IL-1Ra among subjects with
MetS [27]. However there are limited data on gender2 Mediators of Inﬂammation
diﬀerences with respect to CVD and risk factors for CVD in
hypertensive subjects with or without MetS. MetS seems to
be a stronger predictor of CVD in women than in men [28].
Markers of inﬂammation and ﬁbrosis have been shown to
be related to cardiovascular damage in hypertensive subjects
with MetS [29]. The eﬀect of MetS on left ventricular
function and hypertrophy is greater in women than in
men [30]. Furthermore, a high level of hs-CRP is a better
predictor of type 2 diabetes in women than in men [31].
To further investigate the possible gender diﬀerences
relating to MetS and proinﬂammatory markers, adiponectin
and insulin resistance, we studied this question in a
population-based sample of subjects with elevated blood
pressure, with or without MetS.
2.MaterialsandMethods
The study population consisted of 1294 subjects from
Pieks¨ am¨ aki, Eastern Finland. Out of all subjects, who were
born in 1942, 1947, 1952, 1957, and 1962 and invited for a
healthcheck-up,atotalof923(71.3%)decidedtoparticipate
in the study. The study protocol was approved by the Ethics
Committee of Kuopio University Hospital and the University
ofKuopio.Allparticipantsgaveaninformedwrittenconsent.
All subjects having systolic BP ≥130mmHg or diastolic
BP ≥ 85mmHg or receiving antihypertensive medication
were included in the statistical analyses, while subjects with
hs-CRP ≥ 10pg/mL (n = 18) were excluded from the
analysis because of the possibility of acute infections. The
ﬁnal study population consisted of 551 subjects (278 men,
273 women).
All subjects ﬁlled in a questionnaire about their medi-
cation, smoking habits, alcohol consumption, and physical
activity. They were also interviewed by a trained nurse.
Subjects who smoked on a daily basis were considered to be
current smokers. All subjects who used alcohol, regardless
of the amount, were considered to be alcohol users. Subjects
exercising in their free time at least three times a week with
a minimum of 30minutes a time were considered to be
physically active.
BP was measured by a nurse with a mercury sphygmo-
manometer in a sitting position after 15minutes of rest. The
measurement was repeated after ﬁve minutes. The mean of
the two measurements was used in the statistical analyses.
Waist circumference was measured from the midpoint
between the lateral iliac crest and the lowest rib to an
accuracy of 0.5 cm. Weight and height were measured to an
accuracy of 0.1kg and 0.5cm, respectively. Body mass index
(BMI) was calculated as weight (kg) divided by height (m)
squared.
The MetS was deﬁned by the National Cholesterol
Education Program (NCEP) Expert Panel on Detection,
Evaluation and Treatment of High Blood Cholesterol in
Adults (ATP III) criteria. Subjects with three or more of
the following components were classiﬁed as having MetS:
(1) increased waist circumference (≥102cm ≥40 in for
men and ≥88cm ≥35 in for women), (2) elevated fasting
total triglycerides (≥1.7mmol/l ≥150 mg/dl or treatment
for dyslipidemia), (3) low fasting serum high density
lipoprotein (HDL) cholesterol (<1.03mmol/l <40mg/dl in
men or <1.29mmol/l <50mg/dl in women or treatment for
dyslipidemia), (4) systolic BP ≥130mmHg or diastolic BP
≥85mmHg or the use of antihypertensive medication, and
(5) fasting plasma glucose ≥5.6mmol/l ≥100mg/dl or the
use of antihyperglycemic medication.
Fresh serum samples were drawn after an overnight fast.
Plasma was separated by centrifugation for the determina-
tion of fasting insulin, and the samples were frozen imme-
diately. Plasma insulin was determined using the Phadeseph
Insulin radioimmunoassay (RIA) 100 method (Pharmacia
Diagnostics AB, Uppsala, Sweden). Plasma glucose concen-
tration was measured by an automated colorimetric method
(Peridochrom Glucose GOD-PAP, Boehringer, Germany).
Serumtriglyceridesweremeasuredfromfreshserumsamples
by enzymatic colorimetric methods (CHOD-PAP, GPO-
PAP, Boehringer Mannheim GmbH, Germany). Serum HDL
cholesterol was measured by the same method after precip-
itation of low density lipoprotein cholesterol and very low
density lipoprotein cholesterol with phosphotungstic acid
and magnesium. Hs-CRP was measured with an Immulite
analyzer and a DPC high-sensitivity CRP assay (DPL, Los
Angeles, CA, USA). Serum adiponectin was determined with
an enzyme immunoassay (Human Adiponectin ELISA Kit,
B-Bridge International INC, Mountains View, CA, USA).
Plasma concentrations of IL-1Ra were determined with
high-sensitivity assay kits from R&D systems (Minneapolis,
MN,USA).
3.StatisticalAnalysis
The results are expressed as mean ± standard deviation
(SD). The most important outcomes are given with 95 per
cent conﬁdence intervals (95% CI). The Clopper-Pearson
method was used to calculate the conﬁdence interval for
the prevalence rate. The conﬁdence intervals for odds ratios
were obtained by bias-corrected bootstrapping (5000 repli-
cations) [32]. Statistical comparisons between the groups
were performed by chi-square test, t-test, or bootstrap-
type t-test as appropriate. Logistic regression models were
used to investigate the linear association between MetS and
gender-speciﬁc tertiles of insulin, hs-CRP, adiponectin and
inﬂammatory cytokines. We controlled for age, physical
activity, smoking, and use of alcohol in the model 1 and
added BMI for the model 2. The normality of variables
was evaluated by Shapiro-Wilk statistics. No adjustment
was made for multiple testing, but this information can be
obtained by multiplying the actual P-value by the number of
comparisons made.
4. Results
The study population consisted of 278 men and 273 women
with elevated blood pressure. There were no statistically
signiﬁcant gender diﬀerences in the use of antihypertensive
medication (14.4% of men, 14.7% of women, P = .930
between the genders). Mostly used were ace-inhibitors
and B-blockers with no gender diﬀerences. In men, waist
circumference, diastolic BP, triglyceride levels, and fastingMediators of Inﬂammation 3
Table 1: Demographic, clinical, biochemical, and lifestyle factors of subjects.
Variables Men Women P-value
(N = 278) N = 273
Demographic
Age, years 47 (6) 48 (6) 0.38
Age distribution, years 36–57 36–57 NS
Body mass index, kg/m2 27.1 (3.8) 27.1 (5.2) .98
Waist circumference, cm 95 (11) 85 (13) <.001
Clinical
Blood pressure, mmHg
Systolic 146 (15) 144 (14) .10
Diastolic 88 (9) 85 (8) <.001
Medication for hypertension (%) 40 (14) 40 (15) .93
Medication for hyperlipidemia (%) 12 (4.4) 5 (2.0) .092
Medication for diabetes (%) 6 (2.0) 7 (3.0) .75
Biochemical
Total cholesterol, mmol/l 5.9 (1.1) 5.7 (1.0) .11
HDL cholesterol, mmol/l 1.3 (0.3) 1.5 (0.4) <.001
Triglycerides, mmol/l 1.7 (1.4) 1.3 (0.6) <.001
fP-glucose, mmol/l 6.0 (0.7) 5.7 (0.6) <.001
Lifestyle
Number of current smokers (%) 94 (34) 52 (19) <.001
Number of alcohol users (%) 243 (88) 212 (78) <.001
Number of physically active (%) 87 (31) 78 (27) .48
HDL: high density lipoprotein; fP: fasting plasma.
(mean SD in parentheses for continuous variables number of subjects, percentage in parentheses for dichotomous variables).
Table 2: Insulin, hs-CRP, and cytokines according to the presence of metabolic syndrome.
Variables
MetS not present MetS present
Men (n = 181) Women (n = 180) P value† Men (n = 97) Women (n = 93)
P value
†
Mean (SD) Mean (SD) Mean (SD) Mean (SD)
fP-insulin, mU/L 9.2 (4.4) 8.4 (2.8) .065 15.3 (7.8) 15.0 (12.4) .85
hs-CRP, pg/mL 1.32 (1.58) 1.25 (1.37) .65 1.68 (1.70) 2.35 (1.99) .013
Adiponectin, μg/mL 5.02 (2.50) 8.87 (4.84) <.001 4.11 (2.36) 6.64 (3.72) <.001
IL-1Ra, pg/mL 157 (81) 174 (147) .17 212 (208) 289 (242) .014
†Bootstraptypet-test.
MetS: metabolic syndrome deﬁned by the NCEP criteria.
fp: fasting insulin.
hs-CRP: high sensitive C-reactive protein.
IL-1Ra: interleukin 1-receptor antagonist.
glucose were signiﬁcantly higher (P<. 001) and the level of
HDLcholesterolwassigniﬁcantlylower(P<. 001)compared
to women. The number of current smokers and regular
alcohol users was signiﬁcantly higher among men (P<. 001)
than women (Table 1).
MetS was observed in 35% (95% CI: 30% to 41%) of the
men and 34% (95% CI: 29% to 40%) of the women (P = .84
between the genders). There were no statistically signiﬁcant
genderdiﬀerencesinthemeanBMIregardlessofwhetherthe
subjectshadMetS(30.0 ±3.8inmenversus30.9 ±5.1kg/m2
in women, P = .20) or not (25.6 ± 2.7 in men versus 25.2 ±
4.0 kg/m2 in women, P = .27 between the genders).
Table 2 shows the comparison of the levels of fasting
insulin, hs-CRP, and cytokines between the genders in
subjects with and without MetS. In men without MetS,
adiponectin levels were lower compared to those in women
without MetS [−3.85μg/mL (95% CI: −4.72 to −3.10),
P<. 001]. In subjects with MetS, the gender diﬀer-
ence in adiponectin levels between men and women was
−2.53μg/mL (95% CI: −3.44 to −1.68 μg/mL, P<. 001).
In subjects without MetS, no statistically signiﬁcant gender
diﬀerences were observed in any other parameters measured,
but in women with MetS the level of hs-CRP was 0.67pg/mL
(95% CI: 0.13 to 1.17pg/mL, P = .013) and the level of4 Mediators of Inﬂammation
Table 3: Odds ratio (OR) for the presence of metabolic syndrome deﬁned by the NCEP criteria according to the gender-speciﬁc tertiles of
insulin, C-reactive protein, adiponectin and interleukin-1- receptor antagonist in men and women in two adjusted models.
Variables
Men Women
Model 1 Model 2 Model 1 Model 2
OR (95% CI) P-value† OR (95% CI) P-value† OR (95% CI) P-value OR (95% CI) P-value†
fP-insulin <.001 <.001 <.001 .013
1st tertile 1.00‡ 1.00 1.00 1.00
2nd tertile 4.77 (2.01 to 11.34) 3.76 (1.46 to 9.66) 4.61 (1.95 to 10.88) 3.15 (1.27 to 7.80)
3rd tertile 22.02 (9.20 to 52.71) 5.98 (2.20 to 16.23) 17.71 (7.54 to 41.59) 6.00 (2.36 to 15.27)
hs-CRP .12 .26 <.001 .22
1st tertile 1.00 1.00 1.00 1.00
2nd tertile 1.58 (0.84 to 2.97) 0.98 (0.45 to 2.11) 1.76 (0.87 to 3.55) 1.21 (0.55 to 2.65)
3rd tertile 1.65 (0.87 to 3.10) 0.63 (0.28 to 1.42) 4.85 (2.47 to 9.52) 1.65 (0.74 to 3.66)
Adiponectin <.001 .44 <.001 .003
1st tertile 1.00 1.00 1.00 1.00
2nd tertile 0.32 (0.17 to 0.61) 0.67 (0.30 to 1.47) 0.59 (0.32 to 1.09) 0.67 (0.33 to 1.37)
3rd tertile 0.25 (0.13 to 0.49) 0.73 (0.33 to 1.61) 0.25 (0.13 to 0.50) 0.30 (0.14 to 0.67)
IL-1Ra .003 .77 <.001 .068
1st tertile 1.00 1.00 1.00 1.00
2nd tertile 1.68 (0.88 to 3.22) 0.94 (0.43 to 2.06) 3.98 (1.88to 8.43) 2.45 (1.07 to 5.62)
3rd tertile 2.61 (1.37 to 4.94) 1.12 (0.52 to 2.44) 6.80 (3.25 to 14.21) 2.22 (0.94 to 5.24)
Model 1: adjusted for age, physical activity, smoking status, and alcohol use. Model 2: adjusted for age, physical activity, smoking status, alcoholuse, and BMI.
†P-value for linearity.
‡Denominator of odds ratio.
IL-1Ra was 77pg/mL (95% CI: 17 to 141pg/mL, P = .014)
higher than the corresponding levels seen in men.
Table 3 presents the association of gender-speciﬁc tertiles
of fasting insulin, hs-CRP, adiponectin, and proinﬂamma-
tory cytokines with the presence of MetS by gender in two
adjusted models. In men, the odd’s ratio (OR) for MetS was
22.02 (95% CI: 9.20 to 52.71) in the highest tertile of fasting
insulin compared to the lowest tertile after adjustment for
age, physical activity, smoking status, and alcohol use (
Model 1). The corresponding ORs relating to adiponectin
and IL-1Ra were 0.25 (95% CI: 0.13 to 0.49) and 2.61 (95%
C I :1 . 3 7t o4 . 9 4 ) ,r e s p e c t i v e l y .A f t e rf u r t h e ra d j u s t m e n tf o r
BMI (Model 2), only the association of fasting insulin with
the presence of MetS remained statistically signiﬁcant. In
women, the adjusted OR (Model 1) for MetS was 17.71 (95%
CI: 7.54 to 41.59) in the highest tertile of insulin compared
tothelowest tertile.TheORsrelating tohs-CRP,adiponectin
and IL-1Ra were 4.85 (95% CI: 2.47 to 9.52), 0.25 (95% CI:
0.13 to 0.50), and 6.80 (95% CI: 3.25 to 14.21), respectively.
After further adjustment for BMI in women (Model 2), the
associationsbetweenthepresenceofMetSandfastinginsulin
and adiponectin remained statistically signiﬁcant.
5. Discussion
The novel ﬁnding of our study was the gender diﬀerence
in the association of the levels of adiponectin and other
inﬂammatory markers with MetS deﬁned by the NCEP
criteria in subjects with elevated blood pressure. Women
with MetS had higher levels of proinﬂammatory markers
compared to men. Furthermore, absolute diﬀerences in
adiponectin, hs-CRP, and IL-1Ra levels in subjects with and
without MetS were greater in women than in men. The
association between adiponectin levels and the presence of
MetS was statistically signiﬁcant even after adjustment for
BMI in women but not in men.
Hypoadiponectinemia has been shown to be associated
with insulin resistance, coronary artery disease, and central
obesity [12, 13]. Adiponectin is expressed more in subcu-
taneous fat than in visceral fat [12], which explains at least
in part the gender diﬀerence in adiponectin levels in the
general population. Similar results were also obtained in
our study. Furthermore, in subjects with MetS the decrease
in adiponectin levels was relatively greater in women than
in men, and in subjects with MetS the absolute gender
diﬀerence in adiponectin levels was about 1.3μg/ml lower
than that observed in subjects without MetS. Decreased
adiponectin synthesis has been assumed to lead to dysregula-
tion of the control mechanisms inhibiting the production of
proinﬂammatory cytokines [33]. Thus, the greater decrease
in adiponectin levels observed in women could lead to more
proinﬂammation compared to men. Our ﬁnding of higher
absolute and relative cytokine levels in women with MetS
supports this hypothesis.
In our study, a 4-fold higher probability for the presence
of MetS was observed in the lowest adiponectin tertile
compared to the highest adiponectin tertile in both genders.
After adjustment for BMI, this association disappeared in
men but remained statistically signiﬁcant (3-fold) in women.
The greater reduction in adiponectin levels seen in women
with MetS may imply that the role of adiponectin in MetS
is more important in women than in men, at least inMediators of Inﬂammation 5
subjects with elevated blood pressure. This ﬁnding could
be explained by diﬀerences in body composition. Compared
t ow o m e n ,m e nh a v er e l a t i v e l ym o r em u s c l em a s sa n dl e s s
total body fat, which is also more viscerally located. In
women, fat is known to accumulate in the subcutaneous
compartment, especially in the gluteal-femoral region [34].
However, increasing accumulation of visceral fat has also
been observed in women with MetS [35], which probably
leads to a decrease in adiponectin production.
IL-1β is one of the major proinﬂammatory cytokines
synthesized mainly by monocytes and macrophages outside
the fat cell in adipose tissue [18]. Its expression is increased
in visceral adipose tissue in obese subjects [36] and in
patients with essential hypertension [19]. IL-1β stimulates
the release of IL-1Ra which antagonizes IL-1β binding to the
cell receptors [20, 36]. IL-1β levels are not usually elevated in
plasma while anti-inﬂammatory IL-1Ra is constantly present
inthecirculation[20].IncreasesinIL-1β areoftenassociated
with increases in hs-CRP [37], which is synthesized in the
l i v e ri nr e s p o n s et oI L - 1 β. In our study, women with MetS
had higher absolute levels of hs-CRP and IL-1Ra compared
tomenwithMetS.Astatisticallysigniﬁcantgenderdiﬀerence
in the ratio of hs-CRP levels between subjects with and
without MetS was detected in our study, indicating that
the absolute increase in hs-CRP in women with MetS was
greater than that in men with MetS. The gender diﬀerences
in hs-CRP levels vary in diﬀerent studies in the Hoorn study
signiﬁcant association of hs-CRP with incident diabetes
mellitus was observed in men, but not in women [38]. In
Japanese subjects this association was observed in both sexes
[39], but solely in women in the Mexico City Diabetes Study
[40] and in the MONICA/KORA study [31].
Furthermore, there was a larger relative decrease in
the adiponectin level and a larger relative increase in IL-
1Ra levels in women with MetS compared to men with
MetS. All these ﬁndings are in line with previously reported
disturbances in the regulation of inﬂammatory cytokines
associated with decreased adiponectin levels [33].
Elevated plasma insulin is widely used as a marker
of insulin resistance [41], at least in large population
studies where more accurate methods such as the insulin
clamp technique cannot be used. Excessive mobilization of
free fatty acids takes place in the visceral adipose tissue
through a higher rate of lipolysis in visceral fat compared
to subcutaneous fat. High levels of free fatty acids inhibit
insulin-mediated glucose uptake in skeletal muscle leading
to insulin resistance [42, 43]. The increase in circulating
free fatty acids also increases insulin secretion leading to
hyperinsulinemia. In our study, insulin resistance measured
by fasting insulin was similarly associated with MetS in both
genders, showing a 22-fold risk in men and an 18-fold risk in
women in the highest tertile of fasting insulin compared to
the lowest tertile. This risk remained statistically signiﬁcant
even after adjustment for BMI emphasizing the central role
of insulin resistance in MetS.
As far as we know, this is the ﬁrst report in subjects
with elevated blood pressure showing a gender diﬀerence
in the levels of IL-1Ra and hs-CRP in subjects with MetS
deﬁned by the NCEP criteria and a gender diﬀerence in
the relation between adiponectin and the presence of MetS.
The strength of our study is that our sample included ﬁve
entire age groups from one town. The number of subjects
receiving antihypertensive medication was small, meaning
that medication is not likely to bias our results. The relatively
small number of subjects with MetS is a limitation of our
study.
We conclude that gender diﬀerences in inﬂammatory
markers and the relationship between adiponectin levels and
MetS exist in subjects who have elevated blood pressure and
MetS. The signiﬁcance of these ﬁndings necessitates further
research.
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